Mutual of America Capital Management LLC Reduces Stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

Mutual of America Capital Management LLC lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 25.4% in the fourth quarter, Holdings Channel reports. The fund owned 30,982 shares of the company’s stock after selling 10,532 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Apellis Pharmaceuticals were worth $1,855,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of APLS. HC Advisors LLC bought a new position in Apellis Pharmaceuticals in the fourth quarter worth approximately $210,000. Prime Capital Investment Advisors LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth $229,000. China Universal Asset Management Co. Ltd. lifted its position in Apellis Pharmaceuticals by 352.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,710 shares of the company’s stock valued at $821,000 after purchasing an additional 10,682 shares in the last quarter. Altfest L J & Co. Inc. bought a new stake in Apellis Pharmaceuticals during the fourth quarter valued at about $276,000. Finally, Assenagon Asset Management S.A. increased its position in Apellis Pharmaceuticals by 109.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock worth $128,400,000 after buying an additional 1,121,497 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Insider Buying and Selling

In other Apellis Pharmaceuticals news, Director A. Sinclair Dunlop sold 18,681 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total value of $1,068,179.58. Following the transaction, the director now owns 173,998 shares of the company’s stock, valued at approximately $9,949,205.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CFO Timothy Eugene Sullivan sold 1,431 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $96,978.87. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares in the company, valued at approximately $6,325,516.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director A. Sinclair Dunlop sold 18,681 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $57.18, for a total transaction of $1,068,179.58. Following the sale, the director now directly owns 173,998 shares in the company, valued at approximately $9,949,205.64. The disclosure for this sale can be found here. In the last three months, insiders sold 381,011 shares of company stock valued at $23,463,657. Insiders own 7.50% of the company’s stock.

Apellis Pharmaceuticals Trading Up 0.0 %

Shares of APLS opened at $47.53 on Monday. The company’s fifty day simple moving average is $59.71 and its 200-day simple moving average is $57.17. The company has a market cap of $5.73 billion, a P/E ratio of -10.61 and a beta of 0.88. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. Apellis Pharmaceuticals, Inc. has a twelve month low of $19.83 and a twelve month high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. During the same period in the prior year, the company posted ($1.50) EPS. The firm’s revenue for the quarter was up 545.9% on a year-over-year basis. As a group, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.33 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on APLS. Raymond James boosted their price objective on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a “strong-buy” rating in a research note on Thursday, January 11th. Jefferies Financial Group raised shares of Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price objective for the stock from $68.00 to $80.00 in a research note on Monday, February 5th. UBS Group raised their price objective on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Wedbush dropped their target price on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, HC Wainwright reissued a “buy” rating and set a $92.00 target price on shares of Apellis Pharmaceuticals in a research note on Monday, April 15th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $77.93.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).